Physician
ST. Charles Health System, INC.
ST. Charles Health System, INC. was paid $4.96M by Medicaid between Jan 2018 and Dec 2024, across 77 billing codes. Its largest line is 99283, emergency room visit (moderate) — 42% of everything it billed.
33Billing provider infoST. CHARLES HEALTH SYSTEM, INC.
MADRAS, OR 97741
MADRAS, OR 97741
33aNPI1356389894assigned 06/04/2006
33bProvider typeEmergency Medicine Physician
28Total paid$4.96M
24GClaims106,045
24DCodes billed77
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Emergency Medicine Physician providers in Oregon
Rank by total paid#8 of 57
Median peer was paid$62K
This provider vs. median79×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 22,786 | $561K | |
| 2019 | 16,160 | $669K | |
| 2020 | 10,442 | $471K | |
| 2021 | 14,654 | $696K | |
| 2022 | 17,100 | $928K | |
| 2023 | 14,507 | $813K | |
| 2024incomplete | 10,396 | $823K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 42% | 30,048 | 20,988 | $2.08M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 41% | 17,087 | 12,382 | $2.02M |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 5.6% | 1,653 | 1,148 | $276K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 5.0% | 6,341 | 4,861 | $248K |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | 1.9% | 1,100 | 1,042 | $92K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 1,197 | 1,051 | $33K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 13,252 | 11,882 | $32K |
| 80053 | Comprehensive metabolic panel | <1% | 10,861 | 9,788 | $30K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 1,427 | 1,248 | $29K |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 1,353 | 1,162 | $22K |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 765 | 663 | $21K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 653 | 566 | $19K |
65 more codes
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 291 | $8K |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 16 | $7K |
| 93010 | Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | <1% | 919 | $6K |
| 71045 | Radiologic examination, chest; single view | <1% | 197 | $6K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 536 | $6K |
| 36415 | Collection of venous blood by venipuncture | <1% | 5,028 | $6K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 478 | $5K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 1,753 | $4K |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 182 | $3K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 1,636 | $3K |
| 81001 | <1% | 2,406 | $3K | |
| 80061 | Lipid panel | <1% | 1,248 | $2K |
| 83690 | <1% | 611 | $2K | |
| 84484 | <1% | 430 | $1K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 411 | $1K |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 260 | $927.20 |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 29 | $738.81 |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 166 | $536.48 |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 82 | $453.12 |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 34 | $335.30 |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 335 | $276.47 |
| 83605 | <1% | 190 | $264.78 | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 80 | $237.01 |
| J2704 | Injection, propofol, 10 mg | <1% | 122 | $169.84 |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 351 | $145.71 |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 307 | $130.01 |
| 87186 | <1% | 79 | $118.69 | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 121 | $110.25 |
| 83880 | <1% | 16 | $109.92 | |
| 87077 | <1% | 103 | $106.91 | |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 19 | $91.55 |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 110 | $83.07 |
| 83735 | <1% | 16 | $77.38 | |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 50 | $73.58 |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 101 | $51.29 |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 101 | $51.29 |
| 87276 | <1% | 205 | $45.92 | |
| 87275 | <1% | 205 | $41.38 | |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 12 | $28.70 |
| 84466 | <1% | 13 | $22.03 | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 41 | $20.98 |
| 86803 | <1% | 30 | $19.98 | |
| 84703 | <1% | 89 | $18.32 | |
| 83540 | <1% | 13 | $17.67 | |
| 81025 | <1% | 115 | $16.94 | |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 16 | $16.86 |
| 84439 | <1% | 140 | $14.01 | |
| 87088 | <1% | 129 | $5.17 | |
| 85610 | <1% | 26 | $3.84 | |
| 82962 | <1% | 78 | $3.47 | |
| 87210 | 0% | 33 | $0.00 | |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | 0% | 18 | $0.00 |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 0% | 22 | $0.00 |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | 0% | 21 | $0.00 |
| 87807 | 0% | 69 | $0.00 | |
| 85027 | 0% | 17 | $0.00 | |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 0% | 29 | $0.00 |
| 76830 | Ultrasound, transvaginal | 0% | 21 | $0.00 |
| 85379 | 0% | 12 | $0.00 | |
| 87430 | 0% | 12 | $0.00 | |
| 85652 | 0% | 42 | $0.00 | |
| 87081 | 0% | 26 | $0.00 | |
| 82043 | 0% | 15 | $0.00 | |
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | 0% | 31 | $0.00 |
| 86140 | 0% | 14 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialSWAFFORD, MATTHEW (CFO)
| Provider | Location | Paid |
|---|---|---|
| ST. Charles Health System, INC. | Bend, OR | $8.55M |
| ST. Charles Health System, INC. | Bend, OR | $1.38M |
| ST. Charles Health System, INC. | Prineville, OR | $1.37M |
| ST. Charles Health System, INC. | Bend, OR | $539K |
| ST. Charles Health System, INC. | Prineville, OR | $291K |
| ST. Charles Health System, INC. | Bend, OR | $0.00 |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.